Abstracts tagged "diagnosis and systemic lupus erythematosus (SLE)"

Abstract Number: 1690 • 2018 ACR/ARHP Annual Meeting
Increased Sensitivity Οf Τhe New (2017) Αnd Τhe 2012 SLICC As Compared Τo Τhe Acr 1997 Classification Criteria Ιn Early Systemic Lupus Erythematosus (SLE): The 2017 Αnd 2012 Criteria May Classify Non-Overlapping Subgroups Οf Patients
Christina Adamichou¹, Dionysios Nikolopoulos², Alessandra Bortoluzzi³, Emmanouil Papastefanakis¹, Antonis Fanouriakis², Eleni Kalogiannaki¹, Irini Gergianaki¹, Prodromos Sidiropoulos¹ and George Bertsias¹, ¹Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklion, Greece, ²4th Department of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Section of Rheumatology, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliera-University Hospital S. Anna, Cona Ferrara, Italy
Background/Purpose: SLE diagnosis can be challenging especially at the early stages, and existing classification criteria are biased towards classifying patients with long-standing disease. A joined…
Abstract Number: 2086 • 2016 ACR/ARHP Annual Meeting
Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients
Katalin Banki¹, Phillip Aleksiejuk², Jessica Patel² and Andras Perl³, ¹Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ²Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Department of Medicine, Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune, hypercoagulable state which may elicit thrombosis and pregnancy loss. Although several tests exist to guide diagnosis of…
Abstract Number: 2797 • 2016 ACR/ARHP Annual Meeting
Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus
Daniel J Wallace¹, Rosalind Ramsey-Goldman², Anca D. Askanase³, Susan Manzi⁴, Joseph Ahearn⁵, Richard Furie⁶, Arthur Weinstein⁷, Chaim Putterman⁸, Elena Massarotti⁹, Christopher Collins¹⁰, Kenneth Kalunian¹¹, Cristina Arriens¹², Stuart L. Silverman¹³, Smitha Reddy¹⁴, Puja Chitkara¹⁵, Claudia Ibarra¹⁶, Derren Barken¹⁷, Roberta Alexander¹⁸, John Conklin¹⁹ and Thierry Dervieux²⁰, ¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²FSM, Northwestern University, Chicago, IL, ³Medicine, Rheumatology, Columbia University Medical Center, New York, NY, ⁴Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ⁵Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, ⁶North Shore University Hospital, Great Neck, NY, ⁷Rheumatology Section, Washington Hospital Center, Washington, DC, ⁸Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁹Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ¹⁰MedStar Washington Hospital Center, Washington, DC, ¹¹Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ¹²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Cedars, Beverly Hills, CA, ¹⁴Arthritis Care and Research Center, Inc., Poway, CA, ¹⁵Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, ¹⁶Clinical Laboratory, Exagen Diagnostics, Vista, CA, ¹⁷Exagen Diagnostics, Vista, CA, ¹⁸Research & Development, Exagen Diagnostics, Vista, CA, ¹⁹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²⁰Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: A panel of autoantibodies in combination with C4d-bound complement activation products (CB-CAPs, EC4d and BC4d) has been established as a sensitive and specific testing…
Abstract Number: 769 • 2015 ACR/ARHP Annual Meeting
Evaluation of Soluble Alpha-Klotho in Neuropsychiatric Systemic Lupus Erythematosus
Kunihiro Ichinose¹, Takeshi Ushigusa², Masataka Umeda¹, Tomohiro Koga², Atsushi Kawakami² and Shuntaro Sato³, ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan
Evaluation of Soluble alpha-Klotho in Neuropsychiatric Systemic Lupus ErythematosusABSTRACTBackground/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in SLE that presents a variety of…
Abstract Number: 781 • 2015 ACR/ARHP Annual Meeting
Anti-Nucleosome Antibodies Versus Anti-DNA Antibodies in the Diagnosis and Monitoring of Activity of Systemic Lupus Erytematosus
Helena Borrell Paños¹, Javier Narváez², Jordi Bas³, Eulàlia Armengol¹, Maria Aparicio¹, Maria Pascual¹, Mercè López de Recalde¹ and Joan Miquel Nolla¹, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Immunology Department. Hospital Universitari de Bellvitge, Barcelona, Spain
Background/Purpose: Recently, the study of anti-nucleosome antibodies (ANUCs) has been suggested that they may be useful in the diagnosis of systemic lupus erythematosus (SLE) and in…
Abstract Number: 2948 • 2015 ACR/ARHP Annual Meeting
How Do Patients with Newly Diagnosed SLE Present? a Multicenter Cohort Analysis to Inform the Development of New Classification Criteria for SLE
Marta Mosca¹, Zahi Touma², Karen H. Costenbader³, Bimba F. Hoyer⁴, Chiara Tani¹, Alexander Fine⁵, Sara Tedeschi³, Jorge Medina-Rosas⁶, Valentina Lorenzoni⁷, Gian Domenico Sebastiani⁸, Thomas Dorner⁹ and on behalf of the SLE Classification Criteria Steering committee, ¹University of Pisa, Pisa, Italy, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶University of Toronto, Toronto, ON, Canada, ⁷SSSUP, Pisa, Italy, ⁸Osp. San Camillo, Roma, Italy, ⁹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine, Berlin, Germany
Background/Purpose: SLE onset may be insidious with clinically evident disease developing over years. Current SLE classification criteria may not classify patients with early SLE well.…
Abstract Number: 1924 • 2014 ACR/ARHP Annual Meeting
Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus
Rosalind Ramsey-Goldman¹, Richard Furie², Chaim Putterman³, Anka Askanase⁴, Jill P. Buyon⁵, Kenneth Kalunian⁶, W. Winn Chatham⁷, E Massarotti⁸, Kyriakos A. Kirou⁹, A. Weinstein¹⁰, Puja Chitkara¹¹, Susan Manzi¹², Joe Ahearn¹³, Leilani Wolover¹⁴, John Conklin¹⁵, Tyler O'Malley¹⁴, Claudia Ibarra¹⁵, Derren Barken¹⁶ and Thierry Dervieux¹⁷, ¹FSM-300, Northwestern University, Chicago, IL, ²Division of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Department of Medicine Rhemuatology, Colombia University, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Washington Hospital Center, Washington, DC, ¹¹Internal Medicine, Sharp Memorial Hospital, San Diego, CA, ¹²Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ¹³Internal Medicine, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁴Research and Development, Exagen Diagnostics, Inc., Vista, CA, ¹⁵1261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, ¹⁶Exagen Diagnostics, Inc., Vista, CA, ¹⁷rd, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Elevated levels of cell bound complement activation products (CBCAPS) have been established as valuable biomarkers in the diagnosis of Systemic Lupus Erythematosus (SLE). In…
Abstract Number: 1575 • 2013 ACR/ARHP Annual Meeting
Identification Of Novel Distinct Autoantigen Clusters Reflecting The Heterogeneity Of Systemic Lupus Erythematosus
Petra Budde¹, Angelika Lueking¹, Stefan Vordenbäumen², Heike Göhler¹, Martin Gamer¹, Klaus Marquardt¹, Anna Telaar¹, Daniel Chamrad¹, Carmen Theek¹, Peter Schulz-Knappe¹ and Matthias Schneider², ¹Protagen AG, Dortmund, Germany, ²Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Diagnosis of systemic lupus erythematosus (SLE) is based on a combination of clinical findings and laboratory evidence such as anti-nuclear autoantibodies (ANA), anti-Smith and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].